Trade BIOA stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
BioAge Labs, Inc. (BIOA) is trading at US$5.42, down 2.69% today as of Oct 14, 16:00 EDT. The company has a market capitalisation of US$435.1M. Over the past 52 weeks, BIOA has traded between US$5.04 and US$25.96. On Syfe you can trade BIOA with $0 commission and add it to your watchlist.
| Previous close | US$5.57 |
|---|---|
| Market cap | US$435.1M |
| 52-week range | US$5.04 – US$25.96 |
| Volume | 614.84K |
| Exchange | US |
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.
Year: 2024
BioAge Labs Doses First Patient in Phase 2 Trial of BGE-102 in Diabetic Macular Edema
Sep 8, 2:01 PM · MT Newswires
Bioage Labs Insider Sold Shares Worth $1,576,752, According to a Recent SEC Filing
Jul 1, 8:34 PM · MT Newswires
BioAge Labs, Inc. (BIOA) stock is trading at US$5.42, -2.69% from the previous close of US$5.57.
The market cap for BioAge Labs, Inc. (BIOA) stock is approximately US$435.1M.
The 52-week high for BioAge Labs, Inc. (BIOA) stock is US$25.96.
The 52-week low for BioAge Labs, Inc. (BIOA) stock is US$5.04.
BioAge Labs, Inc. (BIOA) does not currently pay a dividend.
Stay on top of BIOA
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
